logo/base Created with Sketch.

An innovative company dedicated to liver health

wave

Our mission

Empowering medical professionals to assess, diagnose and manage chronic liver diseases, everywhere, for simpler, faster and better patient care and liver health.

wave

More about echosens

250

employees over seven subsidiaries

50+

distributors over the world

100+

international patents granted

10.6%

of annual sales invested in R&D

Discover Echosens and our commitment for liver health in video

play
quote

It’s about passionate and humble people that make us see simplicity out of complexity.
Before becoming a company, echosens was an idea. This idea has been growing from its root in Paris, within Prof. Fink’s lab. Initially, my PhD thesis paved the way for the development of transient elastography (TE), which we patented in 1999.

> Continue the story

Laurent Sandrin | Founder and Chief Technology Officer at Echosens

In immersion at Echosens

play

Our vision

At Echosens we envision a future where…

…liver health is at the core of total health.
…every medical professional has the necessary tools to measure the health of the liver, identify pathologies, and manage treatments simply, accurately and effectively.
…every patient has the right to receive information about their liver health in a simple, timely, and easy-to-understand manner.

Using our talents, competencies and passion for innovation and technology, we will build these tools.

We will set the standards for solutions that are ever simpler, more effective, accurate, powerful and non-invasive.

We will empower medical professionals and their patients around the world to better understand liver health.

We will enable them to make the right decisions, and take the right actions, for long-term, total health and well-being.

c Courage
h Humility
o Openness
i Innovation
c Commitment
e Environment
s Simplicity

Inception in Paris

After Laurent Sandrin’s PhD thesis on transient elastography (TE), this technology found its application to quantify liver stiffness (LSM by VCTE) allowing a better patient care in hepatology…

First accomplishment: FibroScan® is born

The very first FibroScan® launched on the market is the FibroScan® 502. It was released during the EASL Congress in Geneva.

CAP™ parameter

In addition to VCTE, Echosens introduced a new, unique and patented technology calledCAP™ (Controlled Attenuation Parameter) for liver steatosis assessment, a true benefit to measure patient’s liver fat.

FibroScan® mobile generation

With FibroScan® Mini+ 430 and FibroScan® Compact 530, the FibroScan® family evolves to better fit physicians daily practice with mobility, user-friendliness and connectivity, ideal for multi-site configuration.

Fast is the optimal point-of-care comprehensive test for the identification of at risk NASH patients.

FibroScan®-based Score: Fast™

The complete non-invasive solution for advanced liver disease management, with the new Spleen Stiffness Measurement (SSM by VCTE™).

Leadership team

Dominique Legros
Group Chief Executive Officer
Jon Gingrich
Chief Executive Officer North America
Lijuan Deng
Chief Executive Officer China
Laurent Sandrin
Founder and Chief Technology Officer